-
1.发明公开
公开(公告)号：EP4401741A1
公开(公告)日：2024-07-24
申请号：EP22801214.2
申请日：2022-09-14
申请人： PALTECH
IPC分类号： A61K31/568 , A61K9/00 , A61P3/08 , A61K38/26
CPC分类号： A61K31/568 , A61K9/0019 , A61P3/08 , A61K9/0024
-
公开(公告)号：EP4380616A2
公开(公告)日：2024-06-12
申请号：EP22808591.6
申请日：2022-07-28
申请人： Vaccinvent GmbH , Universität Ulm
IPC分类号： A61K39/12 , A61P3/08 , A61P3/10 , A61P31/14 , A61P37/00 , C07K16/26 , C07K16/28 , C07K16/42 , C07K16/44
CPC分类号： C07K16/4208 , C12N2770/2003420130101 , A61K2039/50520130101 , A61K2039/50720130101 , C07K16/26 , A61K39/12 , A61P3/08 , A61P3/10 , A61P31/14 , C07K2317/2120130101 , A61P37/00 , C07K2317/3520130101 , C07K2317/5220130101 , C07K2317/7620130101 , C07K2317/9220130101 , C07K16/2887 , C07K2317/2420130101 , A61K2039/57520130101 , A61K2039/5550520130101 , A61K2039/5556120130101
-
-
4.发明授权
公开(公告)号：EP2405903B1
公开(公告)日：2024-04-10
申请号：EP10764152.4
申请日：2010-03-09
IPC分类号： A61K31/202 , A61K31/557 , A61K9/107 , A61K9/20 , A61K9/66 , A61P3/06 , A61P3/08 , A61P5/48 , A61P5/50 , A61K9/48 , A61K9/08 , A23L33/10 , A23L33/115 , A61K31/201 , A61K31/232
-
公开(公告)号：EP3609351B1
公开(公告)日：2024-03-06
申请号：EP18784991.4
申请日：2018-04-10
IPC分类号： A23L33/135 , A23L33/00 , C12N1/20 , A23L33/14 , A23L33/21 , A61K31/715 , A61K31/716 , A61K31/733 , A61P1/00 , A61P3/04 , A61P3/08
-
公开(公告)号：EP4309662A1
公开(公告)日：2024-01-24
申请号：EP22185855.8
申请日：2022-07-19
IPC分类号： A61K35/74 , A23L33/135 , A61P3/08 , A61P3/10 , C12N1/20
摘要： The present invention relates to the field of prevention and/or treatment of metabolic disorders such as obesity, metabolic syndrome, type-2 diabetes, dyslipidemia and insulin resistance.
-
公开(公告)号：EP4263586A1
公开(公告)日：2023-10-25
申请号：EP21839935.0
申请日：2021-12-15
申请人： MedImmune Limited
IPC分类号： C07K14/575 , A61P3/10 , A61P3/08
-
公开(公告)号：EP4218736A3
公开(公告)日：2023-10-18
申请号：EP23158607.4
申请日：2016-12-19
申请人： Afimmune Limited
发明人： CLIMAX, John , COUGHLAN, David
摘要： The present invention relates to the compositions comprising 15-HEPE and methods of treatment relating to same.
-
9.发明授权
公开(公告)号：EP3551188B1
公开(公告)日：2023-10-18
申请号：EP18804193.3
申请日：2018-10-31
发明人： AUGELLI-SZAFRAN, Corinne E. , MOUKHA-CHAFIQ, Omar , SUTO, Mark J. , SHALEV, Anath , THIELEN, Lance , CHEN, Junqin , JING, Gu
IPC分类号： A61K31/517 , A61K31/5377 , C07D413/14 , C07D401/04 , C07D403/04 , C07D413/04 , A61P3/06 , A61P3/08 , A61P3/10
-
公开(公告)号：EP4252766A1
公开(公告)日：2023-10-04
申请号：EP22305435.4
申请日：2022-04-01
发明人： BRECHOT, Christian , AMOUYAL, Gilles , AMOUYAL, Paul , SANTORO, Lyse , ROTH, Fanny , JAMOT, Laure
IPC分类号： A61K38/17 , A61P25/28 , A61P3/08 , A61P3/10 , A61P3/04 , A61P3/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P17/06 , A61P37/00 , A61P27/02 , G01N33/50
摘要： The present invention relates to the use of the HIP/PAP protein, or a derivative thereof, for treating and/or preventing, in an individual in need thereof, a disorder characterized by a CXCL5 level higher in a biological sample of said individual than in a corresponding biological sample of a healthy individual. It also relates to a method for measuring a response to a HIP/PAP protein, or a derivative thereof, in an individual having a disorder characterized by a CXCL5 level higher in a biological sample of said individual than in a corresponding biological sample of a healthy individual and to a method for determining if a disorder in an individual can be treated by the administration, to the said individual, of a HIP/PAP protein, or a derivative thereof.
-
-
-
-
-
-
-
-
-
搜索结果
1063 条记录 (耗时 0.02 秒)
